As a mage, I just want to pursue the truth

Chapter 79 Angel Investment Considerations
Kechuang Biology has completed all the listing procedures, and the listing time is scheduled for October 10, the first working day after the long holiday.

The agency has obtained the shipments of Huaguo brain-computer connected mobile phones in the third quarter.

As one of the shareholders of Kechuang Biotech, IDG listed the brain-computer connection to the mobile phone in its internal smartphone shipment report for calculation.

According to statistics, in the first three quarters of 2021, the shipment volume of brain-computer connected mobile phones was 471 million units, far exceeding expectations.

Because the first brain-computer-connected mobile phone rice mix 4 was only launched in June, it only took one quarter to sell the brain-computer-connected mobile phone.

The organization's internal forecast is that the shipment of brain-computer connected mobile phones will be around 2022 million units in 2000, which can be said to be excellent.

You must know that in the third quarter of 2021, Apple, the largest player in high-end brands, has not yet released their brain-computer connected mobile phones.

The production capacity of the brain-computer connection to the mobile phone has exceeded expectations, although not much.

The time for Apple's fall conference this year has not yet been determined, and Cook has already made a fuss on Twitter:
"The new iPhone is an incredible product!"

"I can't wait for you to use it."

Due to technical limitations, brain-computer connected mobile phones are basically only sold in China, and foreign consumers want to use them either by transferring goods or purchasing them on behalf of others.

As a result, a complete industrial chain has been formed from purchasing brain-computers connected to mobile phones in Huaguo to American, Europa and other places.

Although the recognition accuracy rate of people from English or other languages ​​using a brain-computer connection to a mobile phone is only 70.00%, they cannot hold back the rich electronic product lovers in Europe and the United States.

You only need to spend about 200 yuan more to enjoy the brain-computer connection function. The brain-computer connection device is not much different from the headset, which is completely acceptable to them.

Cook’s tweet was full of sarcasm:

"Another Special Offer from China"

"Apple only cares about the Chinese market"

"It is really convenient to connect a brain-computer to a mobile phone. I have a very good experience using a Chinese-made brain-computer to connect to a mobile phone. It would be great if the accuracy rate can be higher. When will American's product be completed?"

Because the shipments of brain-computer-connected mobile phones exceeded expectations, the agency's internal evaluation of Kechuangbio has been raised to a higher level.

"If we consider the long-term, the price of Kechuang Biology can be bought without thinking if the price is below 3000 yuan."

"Considering the short-term, as long as the price does not hit 2000 yuan on the day of listing, we can build a part of the position." A fund manager said at an internal investment seminar.

"What if 3000 yuan is directly marked on the first day of listing?" asked the assistant.

"Then wait for him to fall, we are not in a hurry to build a position."

"Unless we can get inside information about the progress of research and development in the field of science and innovation in the field of biological brain-computer connection." The fund manager is thinking: "It should not be that difficult, according to my understanding, it should be soon."

"It's a pity that our plate is too big to be aggressive. If it is a private placement price of 3000 yuan, they will dare to charge."

The assistant nodded and said: "Since the R&D center of Kechuang Biology Lion City was stolen, they have changed a group of security guards, and they found a domestic security company in Lion City."

"It is even more difficult to inquire about the news now. Since Zheng Li is in the Lion City, the progress of the Lion City R&D Center will not be reported to Gusu."

The management scale of this fund exceeds 500 billion, which belongs to the top domestic funds, and it is not much worse than the [-] billion scale of Ge Lan and Zhang Kun.

The larger the management scale, the more restrictions are imposed on the fund manager's operations. For example, Zhang Kun's rules allow only about [-] stocks to be traded.

Basically, you can only buy large-cap stocks and blue-chip stocks.

The fund manager feels a headache: "If Kechuangbiology's brain-computer connection technology makes progress before the first half of next year, whether it is the completion of research and development of English-language products, or the new application of brain-computer connection in the medical field."

"I think there's huge room for growth."

With the listing of Kechuang Biotech, Cheng Gang's career has also reached its peak. For the first time, he felt that starting a business is such a simple matter.

Just did some routine work, Kechuang Biology is about to go public, the market value is listed at a valuation of 4000 billion RMB, and the secondary market still thinks this price is too cheap.

Cheng Gang has a deeper understanding of technology as the primary productive force. The failure of his own business back then was due to insufficient technological advantages.

Since Zheng Liyuan left the Lion City, Cheng Gang has essentially become the number one person in the headquarters of Kechuang Biology. Slowly, he began to fight against Li Miaomiao, Zheng Li's spokesperson in the company.

Since Zheng Li is still the absolute controller of the company, even if Kechuang Biotech goes public, Zheng Li still holds more than 50.00% of the shares after the listing.

So Cheng Gang and Li Miaomiao are still friendly on the surface, but in private they are competing for the support of the company's middle management and other executives.

Although Zheng Li is far away in the Lion City, he is very clear about the company's situation. What they know, Zheng Li also knows, and what they don't know, Zheng Li still knows.

On the eve of listing, financial institutions that wanted to operate in the dark not only approached Li Miaomiao, but also other executives of Kechuang Biotech.

Some executives failed to withstand the temptation and chose to accept the other party's sugar-coated cannonballs. Zheng Li sent the two of them for investigation through official channels without going through anyone.

After the incident came out, the company's executives were shocked by Zheng Li's mercilessness, and the company, which was a bit undercurrent, calmed down again.

Cheng Gang didn't dare to do anything to win over the executives and the middle management. He realized that even if Zheng Li wasn't around, he would only be a manager and would not become the actual controller of Kechuang Bio.

Realizing that he is still only a manager, Cheng Gang chose to increase contacts with IDG's Young.

"Young, I plan to cash out part of the shares after Kechuang Biotech goes public and set up an investment fund in the direction of biomedicine."

"At that time we can communicate more."

If Cheng Gang was just the owner of an investment fund company, Young would definitely not have too much contact with him, but Cheng Gang has another identity-the general manager of Kechuang Bio.

"Recently, there is a company that is going to make a C-round investment, and the funding gap is huge. If you have funds in your hand, you can consider whether to follow the investment." Young said.

When Cheng Gang heard about the C round and the large funding gap, he quickly reacted: "Aibo Biological?"

Young nodded: "Yes, it's Aibo Biotech. They want to raise more than 7 million yuan in cash in their C round. So far, seven funds have led the investment."

"Temasek, Invesco Development Market Fund, Zhengxin Stock, Hillhouse, Eli Lilly Asia Fund and Yunfeng Capital."

Some people think that angel investment funds established by Internet companies will not invest in the biomedical industry, but Yunfeng Capital, as the angel investment company of Alima, participated in the lead investment of the C round of Aibo Biotech.

Let's put it this way, angel investment only looks at the quality of the project, and there is no clear standard for what not to invest in and what to invest in.

Lei Jun’s Shunwei Capital’s previous investment in Kechuang Biotech was based on very realistic considerations.

　Thanks to Wactor, a very suave person for the reward!
　　
　
(End of this chapter)